Marinomed Biotech

MARI.VI Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

€14.30

-0.35% today

52W: €11.70 – €21.00

52W Low: €11.70 Position: 28% 52W High: €21.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

2.63x

Price-to-Earnings

Forward P/E

9.6x

Forward Price/Earnings

P/S Ratio

2.71x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$26.4M

Market Capitalization

Revenue Growth

-46.4%

YoY Revenue Growth

Profit Margin

93.41%

Net profit margin

ROE

—

Return on Equity

Beta

—

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

1,121

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

2 analysts

Avg. Price Target

€50.50

+253.15% upside

Target Range

€50.00 – €51.00

About the Company

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company's products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marin

Sector: Healthcare Industry: Biotechnology Country: Austria Employees: 33 Exchange: VIE